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areas such as treatment of ulcers and antihistaminic.[5]
Similarly, the general synthesis of benzimidazoles is by 
the condensation reaction of 1,2-phenylenediamine 
with carboxaldehydes, carboxylic acids,[6,7] or their 
derivatives[8,9] such as, chlorides, nitriles, and orthoesters, 
under strong acidic conditions, with high temperatures. 
Benzimidazoles have also been prepared on a solid phase 
to prove a combinatorial approach.[10] The most popular 
strategies for their synthesis utilize N-alkylation of an 
unsubstituted benzimidazoles.[11] Ammonium salts are 
inexpensive, commercially available reagents for few organic 
transformation reactions such as halogenation of aromatic 
INTRODUCTION
Benzimidazoles and its derivatives represent one of the 
most biologically active class of compounds, possessing a 
wide spectrum of activities and these are well-documented 
in literature. They show selective neuropeptides YY1 
receptor antagonists,[1] potent inhibitors of TIE-2 and 
VEGFER-2 tyrosine kinase receptors,[2] antitumor agents,[3] 
gamma-amino butyric acid (GABA) agonists, and 5-HT3 
antagonists.[4] Substituted benzimidazole derivatives have 
found commercial application in veterinarian medicine 
as anthelmintic agents and in diverse human therapeutic 
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compounds and synthesis of 3, 4-dihydropyrimidine-
2(1H)-ones.[12] However, there are no reports of the 
use of ammonium salts as catalysts for the synthesis 
of benzimidazoles. In continuation, on the synthesis of 
heterocycles[13,14] and on the development of synthetic 
methodologies,[15-17] we herein report a facile method for 
the synthesis of benzimidazoles by the condensation of 
1, 2-phenylenediamine with carbonyl compounds, in the 
presence of ammonium salts in very good yields. Anxiety 
is a psychological and physiological state characterized by 
cognitive, somatic, emotional, and behavioral components. 
These components combine to create an unpleasant feeling 
that is typically associated with uneasiness, fear or worry. 
Anxiety is a generalized mood or condition that occurs 
without an identifiable triggering stimulus. As such, it is 
distinguished from fear, which occurs in the presence of an 
observed threat. Additionally, fear is related to the specific 
behaviors of escape and avoidance, whereas, anxiety is the 
result of threats that are perceived to be uncontrollable 
or unavoidable. Some reports state that benzimidazoles 
possess anti-anxiety activity.[18] This observation prompted 
us to evaluate the synthesized benzimidazole derivatives 
for anti-anxiety activity
MATERIALS AND METHODS
All the chemicals and reagents used were of analytical grade 
and were procured from NICE Chemicals. It is known 
that the  reaction  of  o-phenylenediamine (OPDA) with 
carbonyl compounds,  under  strong  acidic conditions, 
gives benzimidazoles, whereas, OPDA  in the presence 
of β-ketoesters  under neutral  reflux conditions,  gives 
benzodiazepin-2-ones, with the elimination of water and 
alcohol. Under acidic conditions, initially it forms ethyl 
β-2-amino aniline  crotonate at room temperature and 
upon  heating it  gives  2-methyl-1H-benzo[d]imidazole 
instead  of  benzodiazepin-2-ones, with  the  elimination 
of ethyl acetate. Therefore, we have made an attempt to 
react OPDA with carbonyl compounds and b-ketoesters, 
with different ammonium salts to see the feasibility of the 
formation of  compounds. To select  favorable reaction 
conditions, we first examined the model reaction of 1, 
2-phenylenediamine  (1 mol) with benzaldehyde (1 mol) 
in the presence of NH4Br  (1 mol), under  solvent-free 
conditions, at  room  temperature.  The  reaction  was 
monitored  by thin-layer chromatography (TLC, eluent 
Hexane/ethyl acetate 30/70) and 2-phenyl-1H-benzo[d]
imidazole obtained in 20% yield.  Similarly, the reaction 
was  conducted  in  different  solvents  such as CH
3CN, 
MeOH,  CHCl
3,  ether, and DMF;  CHCl
3  was found to 
be the most  suitable  solvent  that gave benzimidazole 
with 40% yield. Next, we carried out the same reaction 
with different ammonium salts such as NH
4F, NH
4Cl, 
NH
4NO
3, (NH
4)
2CO
3, and (NH
4)
2SO
4 in the presence of 
CHCl
3, at room temperature; among these, NH
4Cl (4 mol) 
gave 2-phenyl-1H-benzo[d]imidazole with 94% yield in 4 
hours [Figure  1, Table 1]. The results, tabulated in Table 
2, indicate the formation of benzimidazoles.
The synthesized compounds were analyzed by NMR, Mass, 
and IR spectroscopy.1H  NMR spectra  were recorded 
on a Varian  Gemini  200- and  300-MHz instrument in 
CDCl
3 and DMSO-d6 using Tetramethylsilane (TMS) as 
an internal standard. The mass spectra were measured 
on a Liquid Chromatography / Mass Spectrometry 
(LCMS) Agilent mass spectrometer. The IR spectra were 
recorded on  a Nicolet  740 Fourier transform infrared 
(FTIR) spectrometer. The melting points were measured 
using a Buchi-510 apparatus and were uncorrected.
Typical Experimental Procedure for the Synthesis of 
Benzimidazoles
Benzaldehyde  (Y,  1 mmol)  was  added  to  a  stirred 
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Table 2: Synthesis of benzimidazole derivatives
S.NO OPDA (X) ALDEHYDE 
(Y)
TIME 
(hr)
PRODUCT  
(Z)
YIELDa M.P (oC)
A
 
 
NH2
NH2
CHO 4 N
N
H
94  294 – 296
(295 – 297)[19]
B
 
 
NH2
NH2
CHO
OH
6 N
N
H
OH
78 272 – 274 (271)[19]
C  
NH2
NH2 O2N
CHO 10 N
N
H
O2N
82  206 – 209
(207 – 208)[20]
D
 
 
NH2
NH2
CHO
OCH3
6 N
N
H
OCH3
85  230 – 232
(284 – 288)[21]
E
 
 
NH2
NH2
CHO
CH3
6 N
N
H
CH3
88  278 – 282
(277 – 278)[21]
F  
NH2
NH2 O2N
CHO
OH
18 N
N
H
OH
O2N
76  234 – 236
(237 – 238)[22]
G  
NH2
NH2 O2N
CHO
CH3
16 N
N
H
CH3
O2N
86 221 – 224
H  
NH2
NH2 C H3
CHO
OH
14 N
N
H
OH
C H3
82 244 – 246
aIsolated and unoptimized yields, All the compounds (ZA-H) were spectral data (1H NMR, IR, and MS) and compared with authentic samples
Table 1: Optimization of reaction conditions for 
the synthesis of 2-phenyl benzimidazole by the 
condensation of OPDA, with benzaldehyde, using 
various ammonium salts at room temperature in 
CHCl3
NH4Xa Time (hours) Yield (%)b
NH4Br 4 86
NH4Cl 4 92
NH4F 5 72
(NH4)2SO4 12 78
(NH4)2CO3   82
aReaction carried out with 4 mol of NH4X, bIsolated and unoptimized yields
solution  of  1,2-phenylenediamine (X, 1 mmol)  and 
NH
4Cl  (4 mmol) in CHCl3  (5 ml) for five minutes at 
room temperature. Stirring was continued for four hours. 
After completion of the reaction (TLC, eluent Hexane / 
ethyl acetate 30 / 70),  the solvent  was removed  under 
reduced  pressure  and extracted  with ethyl acetate  (20 
ml); the organic  layer was washed with water  (10 ml). 
Layers were separated  and the organic  layer was dried 
over  sodium sulfate.  The solvent  was  removed under 
reduced pressure and the crude product was subjected to 
column chromatography using petroleum ether = EtOAc 
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(9:1), which gave 2-phenyl-1H-benzo[d]imidazole (ZA) as 
a solid in 94% yield.
Spectral Data
2-phenyl-1H-benzimidazole:
Solid;  Molecular  formula:  C13H10N2, Yield-94%, 
m.p-296  oc;1H  NMR:  δ 6.06 (bs,  1H,  NH),  6.82 
( d , 2 H , aromatic) ,  6.98 ( d , 2 H ,  aromatic) ,  7.06 
(t, 1 H ,  aromatic), 7.28 (m, 2H, aromatic), 7.52 (m, 2H, 
aromatic),  IR  (KBr):  3426(-NH), 3042(Ar-CH), 1742, 
1631(-C = N) cm-1; Mass (LCMS): m/z 195 (M+ + H).
4-(1H-benzimidazol-2-yl) phenol:
Solid; Molecular formula:C13H10N2O, Yield - 78%, 
m.p-271  oc; 1H  NMR:  δ 6.06 (bs,  1H,  NH),  6.82 
( d , 2 H , aromatic) ,  6.98 ( d , 2 H ,  aromatic) ,  7.21 
(d , 2 H ,   aromatic), 7.52 (d, 2H, aromatic), IR  (KBr): 
3379(-NH), 3211(-OH), 3078(-Ar-CH), 1461(C = N) cm-1; 
Mass (LCMS): m/z 211 (M+ + H).
6-nitro-2-phenyl-1H-benzimidazole:
Solid; Molecular formula:C13H9N3O2, Yield -82%, 
m.p-208  o c; 1H  NMR:  δ 6.08 (bs, 1H,  NH),  6.90 
( d , 2 H , aromatic) ,  6.96 ( d , 2 H ,  aromatic) ,  7.05 
(t, 1 H ,   aromatic),  7.54 (d , 1 H ,   aromatic), 8.12 (d, 
1H, aromatic), 8.44 (s, 1H, aromatic), IR (KBr): 3211(-
NH), 2984(Ar-CH), 1552(-NO2), 1529(-C=N) cm-1; Mass 
(LCMS): m/z 240 (M+ +H).
2-(4-methoxyphenyl)-1H-benzimidazole:
Solid; Molecular formula:C14H12N2O, Yield -85%, m.p-
285 o c; 1H NMR: δ 3.70 (d,3H, OCH3), 6.12 (bs, 1H, 
NH), 6.94 (d , 2 H , aromatic),  6.98(d , 2 H ,  aromatic), 
7.20 (d , 2 H ,   aromatic),  7.58 (d , 2 H ,   aromatic),  IR 
(KBr):  3294(-NH), 3103(Ar-CH), 1184 (-OCH3), 1588(-
C=N) cm-1; Mass (LCMS): m/z 225 (M+ +H).
2-(4-methylphenyl)-1H-benzimidazole:
Solid; Molecular formula:C13H12N2, Yield -88%, m.p-
278 o c; 1H NMR:  δ 2.54 (d,3H,CH 3),6.06 (bs, 1H, 
NH), 6.84 (d ,2 H ,aromatic),  6.96 (d , 2H , aromatic), 
7.18 (d,2H, aromatic),7.58 (d, 2H, aromatic), IR (KBr): 
3346(-NH), 3024(Ar-CH), 2923(-CH3), 1575(-C=N) cm-1; 
Mass (LCMS): m/z 209 (M+ +H).
4-(6-nitro-1H-benzimidazol-2-yl) phenol:
Solid; Molecular formula:C13H9N3O3, Yield -76%, 
m.p-237  o c; 1H NMR:  δ 6.08 (bs, 1H, NH),  6.74 (d, 
2H, aromatic), 6.84 (d, 2H,  aromatic),  7.45 ( d , 1 H , 
aromatic) ,  8.02 ( d , 1 H ,   aromatic) , 8.32 (s, 1H, 
aromatic), IR (KBr): 3737(-OH),3432(-NH), 3103(Ar-
CH), 1562(C=N), 1532(-NO2) cm-1; Mass (LCMS): m/z 
256 (M+ +H).
2-(4-methylphenyl)-6-nitro-1H-benzimidazole:
Solid; Molecular formula:C14H14N3O2, Yield -86%, 
m.p-223  o c; 1H  NMR:  δ 2.56 (d,3H,CH 3),6.10 
(bs, 1H,  NH),  6.80 (d , 2 H , aromatic),  6.86 (d , 2 H , 
aromatic) ,  7.54 ( d , 1 H ,   aromatic) , 8.08 (d, 2H, 
aromatic), 8.44 (s, 1H, aromatic), IR (KBr): 3402(-NH), 
3054(Ar-CH), 1534(-C=N), 1524(-NO2) cm-1; Mass 
(LCMS): m/z 254 (M+ +H).
4-(6-methyl-1H-benzimidazol-2-yl) phenol:
Solid; Molecular formula:C14H12N2O, Yield -82%, m.p-
245 o c; 1H NMR: δ 2.56 (d,3H,CH 3), 6.48 (bs, 1H, 
NH), 6.78 (d ,2 H ,aromatic),  6.92 (d , 2H , aromatic), 
7.48 ( d , 1 H ,   aromatic) ,  8.10 ( d , 1 H ,   aromatic) , 
8.44 (s, 1 H ,   aromatic),  IR (KBr): 3455(-OH), 3274(-
NH), 3212(Ar-CH), 2898(-CH3), 1534(-C=N) cm-1; Mass 
(LCMS): m/z 225 (M+ +H).
Pharmacology
Wistar rats weighing 200  ±  25 g, of either sex, were 
procured at least two weeks prior to the study. The animals 
were housed in polycarbated cages under conditions of 
constant temperature (22  ±  2o C) and humidity, under a 
12-hour light / dark schedule, The animals were allowed 
free access to a standard diet and water, so they could 
acclimatize to the new environment. 
Acute oral toxicity studies
The aim of this study is to determine the lethal dose. In this 
study the testing drug was administered in a single dose, 
using the oral route. The dose was increased in a graded 
manner. LD50 in the acute toxicity test was observed at 
the dose of 400 mg/kg-bw. Therefore, one-tenth of the 
preceding dose (200 mg/kg-bw) was selected for the study, 
that is, 20 mg/kg-bw. This 20 mg/kg-bw testing dose did 
not have any impact on the normal locomotion of the 
animal, which was tested by administering the same dose 
to the animals, using the oral route. The locomator activity 
was assessed in an actophotometer.
Anti-anxiety activity
In this activity, the elevated plus maze model was used. For 
this model, Wistar rats were divided into 10 groups of six 
animals each. Group-I (control) animals were administered 
the vehicle, Group-II, Group-III, Group-IV, Group-V, 
Group-VI, Group-VII, Group-VIII, and Group-IX 
animals were administered the benzimidazole derivatives 
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of ZA – ZH, respectively, with a dose of 20 mg/kg-bw 
(p.o), and Group-X was administered diazepam 2 mg/kg-
bw (p.o), for 1 day in case of acute study and for 10 days 
in case of chronic study. The number of entries and time 
spent in the open and closed arms of the elevated plus 
maze, using rats, was observed in acute and chronic studies 
for 1day and 10 days, respectively. Diazepam was used as 
a reference standard. The experiment was conducted in a 
sound attenuated room. In an acute study, the animals of 
all groups were treated with the respective drugs 30 minutes 
prior to the experiment. In a chronic study, animals of all 
groups were treated with the respective drugs for 10 days, 
and on the tenth day, treatment was given 30 minutes prior 
to the experiment. In both acute and chronic studies, each 
rat was placed in the center of the maze facing one of 
the enclosed arms, and during a ten-minute session the 
following parameters were noted; Number of entries into 
the open arm, number of entries into the closed arm, time 
spent in the open arm, time spent in the closed arm, and 
total number of entries into the open and closed arms.[23,24]
Statistical Analysis
The values were expressed as mean  ±  SEM for six 
animals. The results were subjected to statistical analysis 
by using one-way ANOVA followed by Tukey-Kramer test, 
to calculate the significant difference, if any, among the 
groups. P < 0.05 was considered as significant. 
RESULTS
The compounds (ZA – ZH) were obtained by the reaction 
between aldehyde and o-phenylediamine in the presence of 
ammonium salts according to Figure 1. The synthesized 
compounds were confirmed by thin layer chromatography 
(TLC), Melting Point (mp), IR,  1H NMR, and mass 
spectroscopy (MS) spectral analysis. The yields and 
melting points for all the synthesized compounds are 
listed in Table 2. The titled compounds were confirmed 
by IR spectral data showing characteristic bands at 1384 
– 3200 cm-1, indicating the presence of –NO2 and –OH 
stretching; and sharp bands, ranging between 1680 – 1750 
cm-1, indicating the presence of C = N. Compounds ZA – 
ZH were confirmed by stretching at 3500 cm-1, due to the 
presence of –NH. Compounds ZA – ZH were confirmed 
by 1H NMR spectral analysis. The NMR proton peak at 
6.00 – 6.18 ppm revealed the presence of –NH. Further 
appearance of the molecular ion peak at 225 (m + 1) 
and 209 (m + 1) confirmed the structure of ZD and ZE. 
The synthesized compounds ZB, ZE, ZF, ZG, and ZH were 
found to have potent anti-anxiety activity. Compound ZH 
exhibited more activity when compared to other prepared 
benzimidazoles.
Anti-anxiety activity
In the acute and chronic studies of elevated plus maze 
models [Tables 3 and 4], the number of entries into the 
open and closed arms and the time spent in the open 
arm were increased; and time spent in the closed arm was 
decreased in synthetic preparation-treated animals when 
compared with the control animals, which was comparable 
with that of the reference standard, diazepam.
DISCUSSION
Several researchers reported a synthesis of benzimidazole 
derivatives, but in our present study we synthesized the 
benzimidazole derivatives by using ammonium salts 
as catalysts, which were inexpensive and decreased the 
reaction time, with very good yields. This method could be 
easily practiced in laboratories within the stipulated time.
In the evaluation of anti-anxiety activity, the experimental 
model used in our study was an elevated plus maze. 
This was based on the assumption that unfamiliar, non-
protective, and brightly lit environmental stress provoked 
inhibition of normal behavior. This normal behavioral 
inhibition was further augmented in the presence of fear 
or an anxiety-like state.[24] The elevated plus maze test 
was a well-established animal model for testing anxiolytic 
drugs. A known anxiolytic drug, diazepam, was used as the 
standard, which is one of the well-recognized anxiolytic 
drugs. In this model, the changes that occurred due to 
anxiety were, decreased time spent in the open arm, 
increased time spent in the closed arm, and decreased 
number of entries between the arms, than that which was 
observed in the control animals.
After treatment with the synthetic preparation, at a dose 
of 20 mg/kg-bw, the compounds ZB, ZE, ZF, ZG, ZH, and 
the standard, significantly increased the time spent in the 
open arm, decreased the time spent in the closed arm, and 
increased the number of entries between the arms, in the 
acute study [Table 3]. All these may be due to decreased 
fear, increased exploratory behavior, and the behavioral 
disinhibitory effect[24] of the standard (Diazepam) and 
synthetic preparation. Similar findings were observed in the 
chronic study also [Table 4]. This may be due to the same 
mechanism, as stated earlier in the acute study.
CONCLUSION
The present study describes a simple, inexpensive, and 
easy method for synthesis of benzimidazole derivatives 
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Table 3: Effect of synthetic preparation on number of entries and time spent in elevated plus maze in acute study
Treatment group Open arm entries Closed arm entries Total entries Time spent in open arm Time spent in closed arm
Control 2.5 ± 0.4282 2.16 ± 0.3073 4.66 ± 0.6667 16.83 ± 1.352 583.16 ± 1.352
ZA 3.83 ± 0.3070 3.66 ± 0.4216 7.5 ± 0.7188 23 ± 1.673 577 ± 1.673
ZB 4.50 ± 0.5627 4.33 ± 0.7149* 8.83 ± 1.249* 35.5 ± 1.310* 564.5 ± 1.310*
ZC 4.16 ± 0.4773 3.83 ± 0.4773 8 ± 0.8563 19.83 ± 1.249 580.16 ± 1.249
ZD 2.66 ± 0.3333 3 ± 0.2582 5.66 ± 0.4216 17.83 ± 1.579 582.16 ± 1.579
ZE 5.16 ± 0.4773* 4.83 ± 0.3073** 10 ± 0.6831** 92.16 ± 6.085*** 507.83 ± 6.085***
ZF 5 ± 0.3651* 5 ± 0.4475*** 10 ± 0.6831** 101.66 ± 3.432*** 498.33 ± 3.432***
ZG 5.16 ± 0.6009* 5 ± 0.3651*** 10.16 ± 0.9098** 104.33 ± 3.658*** 495.66 ± 3.658***
ZH 5.66 ± 0.7601** 5.66 ± 0.3333*** 11.33 ± 1.685*** 115.33 ± 4.835*** 484.66 ± 4.835***
Std (Dizepam) 6.5 ± 0.4282*** 6.83 ± 0.4773*** 13.33 ± 0.8028*** 134.16 ± 4.430*** 465.83 ± 4.430***
Significance: All values are given in mean ± SEM, n ═ 6. One way ANOVA followed by Tukey’s multiple comparison test, ***P < 0.001, **P < 0.01, *P < 0.05 vs. control
Table 4: Effect of synthetic preparation on number of entries and time spent in elevated plus maze model in chronic 
study
Treatment group Open arm entries Closed arm entries Total entries Time spent in open arm Time spent in closed arm
Control 3.83 ± 0.3073 3.83 ± 0.3073 7.66 ± 0.4216 19 ± 1.211 581 ± 1.211
ZA 4.83 ± 0.3073 4.16 ± 0.3073 9 ± 0.4472 24.5 ± 1.784 575.5 ± 1.784
ZB 6.66 ± 0.7149** 7 ± 0.577** 13.66 ± 1.229*** 85.5 ± 2.291*** 514.5 ± 2.291***
ZC 5.16 ± 0.4773 5.16 ± 0.4773 10.33 ± 0.8433 25.33 ± 1.60 574.66 ± 1.60
ZD 3.83 ± 0.3073 4.16 ± 0.4773 8 ± 0.6831 25.33 ± 2.275 574.66 ± 2.275
ZE 6 ± 0.2582* 6 ± 0.3651 12 ± 0.4472* 97.83 ± 4.003*** 502.16 ± 4.003***
ZF 6.16 ± 0.3073* 6.5 ± 0.4282* 12.66 ± 0.646** 106.16 ± 2.040*** 493.83 ± 2.040***
ZG 6.33 ± 0.6146** 6.33 ± 0.8433* 12.66 ± 1.406** 111.66 ± 2.246*** 488.33 ± 2.246***
ZH 6.83 ± 0.7032*** 6.83 ± 0.6009** 13.66 ± 1.229*** 121 ± 3.307*** 479 ± 3.307***
Std (Dizepam) 7.5 ± 0.4282*** 7.83 ± 0.6009*** 15.33 ± 0.9545*** 136.33 ± 2.985*** 463.66 ± 2.985***
Significance: All values are given in mean ± SEM, n ═ 6. One way ANOVA followed by Tukey’s multiple comparison tests, ***P < 0.001, **P < 0.01, *P < 0.05 vs. control
in a stipulated time, without using any drastic conditions. 
The yield of all benzimidazole derivatives were found to 
be in the range of 75 – 94%. The purity of the compounds 
were ascertained by a melting point and TLC. The assigned 
structure was further established by IR, 1HNMR, and MS 
spectral studies.
The acute and chronic studies for anti-anxiety activity of 
the synthesized compounds were screened using elevated 
plus maze method in Wistar rats. Diazepam was used as the 
reference drug. In the prepared benzimidazole derivatives, 
it seemed that the compounds ZB [4-(1H-benzimidazol-2-
yl) phenol], ZE [2-(4-methylphenyl)-1H-benzimidazole], 
ZF [4-(6-nitro-1H-benzimidazol-2-yl) phenol], ZG 
[2-(4-methylphenyl)-6-nitro-1H-benzimidazole], and ZH 
[4-(6-methyl-1H-benzimidazol-2-yl) phenol] showed potent 
activity when compared to the standard drug diazepam. The 
compound ZH [4-(6-methyl-1H-benzimidazol-2-yl) phenol] 
exhibited the highest anti-anxiety activity when compared 
to the other prepared benzimidazole compounds.
From the present study, it can be concluded that the 
benzimidazole derivatives can potentially be developed 
into useful anti-anxiety agents, which can prompt future 
researchers to synthesize a series of benzimidazole 
derivatives containing a wide variety of substituent’s, with 
the aim of producing a novel heterocyclic system, with 
enhanced activity.
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